What makes LPOXY’s approach to C. difficile prevention different

We’re grateful for this thoughtful write-up by Jesse Landry on what makes LPOXY’s approach to C. difficile prevention different, and we’re looking forward to advancing SIDIPREV™ in the STOP-Cdiff trial.

Jesse Landry, Vention Senior Exec. and startup enthusiast, shares his views on our latest announcement on securing $28 million dollars in Series A financing, led by 5 Horizons Ventures, fuelling LPOXY’s registrational STOP-Cdiff pivotal trial:

“SIDIPREV™, an enteric-coated, metered-dose oxygen capsule designed to release in the colon. The science is elegantly blunt, deliver oxygen where C. diff wants none, block toxin production, cool down inflammation, and tilt the odds back in favor of the patient. It is a non-antibiotic approach, which means no tug-of-war with resistance and none of the stewardship headaches that bog down traditional drug rollouts. If it works at scale, hospitals could see fewer recurrences, fewer complications, and fewer penalties under fixed-payment models. Translation: lives saved, costs cut, margins protected,” Jesse Landry.

Read the full post below and view our Pipeline Progress here.